

Surveillance for Adverse Events After COVID-19 mRNA Vaccination

Nicola P. Klein, MD, PhD; Ned Lewis, MPH; Kristin Goddard, MPH; Bruce Fireman, MA; Ousseny Zerbo, PhD; Kayla E. Hanson, MPH; James G. Donahue, DVM, PhD; Elyse O. Kharbanda, MD, MPH; Allison Naleway, PhD; Jennifer Clark Nelson, PhD; Stan Xu, PhD; W. Katherine Yih, PhD, MPH; Jason M. Glanz, PhD; Joshua T. B. Williams, MD; Simon J. Hambidge, MD, PhD; Bruno J. Lewin, MD; Tom T. Shimabukuro, MD, MPH, MBA; Frank DeStefano, MD, MPH; Eric S. Weintraub, MPH

 Editorial

 Supplemental content

IMPORTANCE Safety surveillance of vaccines against COVID-19 is critical to ensure safety, maintain trust, and inform policy.

OBJECTIVES To monitor 23 serious outcomes weekly, using comprehensive health records on a diverse population.

DESIGN, SETTING, AND PARTICIPANTS This study represents an interim analysis of safety surveillance data from Vaccine Safety Datalink. The 10 162 227 vaccine-eligible members of 8 participating US health plans were monitored with administrative data updated weekly and supplemented with medical record review for selected outcomes from December 14, 2020, through June 26, 2021.

EXPOSURES Receipt of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) COVID-19 vaccination, with a risk interval of 21 days for individuals after vaccine dose 1 or 2 compared with an interval of 22 to 42 days for similar individuals after vaccine dose 1 or 2.

MAIN OUTCOMES AND MEASURES Incidence of serious outcomes, including acute myocardial infarction, Bell palsy, cerebral venous sinus thrombosis, Guillain-Barré syndrome, myocarditis/pericarditis, pulmonary embolism, stroke, and thrombosis with thrombocytopenia syndrome. Incidence of events that occurred among vaccine recipients 1 to 21 days after either dose 1 or 2 of a messenger RNA (mRNA) vaccine was compared with that of vaccinated concurrent comparators who, on the same calendar day, had received their most recent dose 22 to 42 days earlier. Rate ratios (RRs) were estimated by Poisson regression, adjusted for age, sex, race and ethnicity, health plan, and calendar day. For a signal, a 1-sided $P < .0048$ was required to keep type I error below .05 during 2 years of weekly analyses. For 4 additional outcomes, including anaphylaxis, only descriptive analyses were conducted.

RESULTS A total of 11 845 128 doses of mRNA vaccines (57% BNT162b2; 6 175 813 first doses and 5 669 315 second doses) were administered to 6.2 million individuals (mean age, 49 years; 54% female individuals). The incidence of events per 1 000 000 person-years during the risk vs comparison intervals for ischemic stroke was 1612 vs 1781 (RR, 0.97; 95% CI, 0.87-1.08); for appendicitis, 1179 vs 1345 (RR, 0.82; 95% CI, 0.73-0.93); and for acute myocardial infarction, 935 vs 1030 (RR, 1.02; 95% CI, 0.89-1.18). No vaccine-outcome association met the prespecified requirement for a signal. Incidence of confirmed anaphylaxis was 4.8 (95% CI, 3.2-6.9) per million doses of BNT162b2 and 5.1 (95% CI, 3.3-7.6) per million doses of mRNA-1273.

CONCLUSIONS AND RELEVANCE In interim analyses of surveillance of mRNA COVID-19 vaccines, incidence of selected serious outcomes was not significantly higher 1 to 21 days postvaccination compared with 22 to 42 days postvaccination. While CIs were wide for many outcomes, surveillance is ongoing.

JAMA. doi:10.1001/jama.2021.15072
Published online September 3, 2021.

Author Affiliations: Author affiliations are listed at the end of this article.

Corresponding Author: Nicola P. Klein, MD, PhD, Kaiser Permanente Vaccine Study Center, 1 Kaiser Plaza, 16th Floor, Oakland, CA 94612 (nicola.klein@kp.org).

Safe and effective vaccines against SARS-CoV-2 are critical to ending the pandemic. Two messenger RNA (mRNA) vaccines (BNT162b2, Pfizer-BioNTech; and mRNA-1273, Moderna) were the first SARS-CoV-2 vaccines authorized in the US.^{1,2} Large phase 3 trials for BNT162b2 and mRNA-1273 demonstrated that both vaccines were more than 94% effective against symptomatic SARS-CoV-2 infection.^{3,4} Neither trial reported serious safety findings, and both observed low incidence of serious adverse events.

The BNT162b2 vaccine received an Emergency Use Authorization on December 11, 2020¹; mRNA-1273, on December 18, 2020.² Vaccinations began in mid-December.⁵

Rare or serious outcomes associated with a vaccine may not be identified in phase 3 trials because of limited sample size, restrictive inclusion criteria, limited duration of follow-up, and trial participants who may differ from the population ultimately receiving the vaccine. Furthermore, there is limited experience with mRNA platforms.⁶ Surveillance is critical to ensure safety, maintain trust, and inform policy.

Since 2006, the Vaccine Safety Datalink,⁷ a collaboration between US health plans and the Centers for Disease Control and Prevention (CDC), has conducted weekly vaccine surveillance known as rapid cycle analysis.⁸⁻¹¹ When the first COVID-19 vaccine was administered in December 2020, weekly monitoring started immediately. This report includes interim findings on risk of adverse events after receipt of mRNA COVID-19 vaccines through June 2021.

Methods

This study was approved by the institutional review boards of all participating health plan sites, with a waiver of informed consent, and was conducted consistent with federal law and CDC policy.

Setting and Study Population

The population covered by the 8 data-contributing health plans comprises 12 506 658 people, representing 3.6% of the US population, and includes all ages, with approximately 16% aged 65 years or older and 20% younger than 18 years. Participating sites (Kaiser Permanente: Colorado, Northern California, Northwest, Southern California, and Washington; Marshfield Clinic; HealthPartners; and Denver Health) have comprehensive medical records for their members.

Participating sites routinely create dynamic files that are updated weekly and contain information on demographics (including race and ethnicity in fixed categories based on self-reported data from the participating health plans), immunizations, and diagnosis codes associated with all outpatient, emergency, and hospital encounters. Sites included race and ethnicity to identify disparities regarding vaccination rates.^{12,13} In response to the pandemic, we created additional weekly files, including COVID-19 diagnoses and laboratory results. Surveillance included the 10 162 227 members of participating health plans aged 12 years or older.

Vaccination date, manufacturer, and dose number for each COVID-19 vaccine were recorded at the participating sites for

Key Points

Question Are mRNA COVID-19 vaccines associated with increased risk for serious health outcomes during days 1 to 21 after vaccination?

Findings In this interim analysis of surveillance data from 6.2 million persons who received 11.8 million doses of an mRNA vaccine, event rates for 23 serious health outcomes were not significantly higher for individuals 1 to 21 days after vaccination compared with similar individuals at 22 to 42 days after vaccination.

Meaning This analysis found no significant associations between vaccination with mRNA COVID-19 vaccines and selected serious health outcomes 1 to 21 days after vaccination, although CIs were wide for some rate ratio estimates and additional follow-up is ongoing.

the doses they delivered. All sites also capture COVID-19 vaccines administered outside of their health care system, including those administered in nursing homes, retail pharmacies, and government-run vaccination clinics; self-reported vaccinations; and those recorded in state immunization registries. This report includes only mRNA vaccines.

Study Design

Each week since December 14, 2020, when vaccinations against COVID-19 began, we updated and analyzed all vaccinations and outcomes in the surveillance population. We analyzed the accumulating data to regularly update the Advisory Committee on Immunization Practices and address emerging vaccine safety concerns that arose elsewhere. The primary analyses compared outcome rates during risk intervals for individuals recently vaccinated with rates during comparison intervals for those less recently vaccinated. The surveillance protocol, including planned analyses not presented here, is available at <https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/emergencypreparedness/index.html>.

Our COVID-19 vaccine surveillance is anticipated to continue for a minimum of 2 years. This interim report includes mRNA vaccinations and outcome events from December 14, 2020, through June 26, 2021.

Outcomes

We targeted 23 serious outcomes after consultation with CDC and study investigators in coordination with partners from the Food and Drug Administration, Department of Defense, and Department of Veterans Affairs (Table 1). We selected outcomes based on (1) inclusion in prior vaccine safety studies (acute disseminated encephalomyelitis, anaphylaxis, encephalitis/myelitis, Guillain-Barré syndrome, immune thrombocytopenia, Kawasaki disease, narcolepsy, seizures, and transverse myelitis); (2) imbalances in phase 3 COVID-19 vaccine clinical trials (appendicitis, Bell palsy); (3) hypothetical concerns regarding an association with COVID-19 disease (acute myocardial infarction, acute respiratory distress syndrome, disseminated intravascular

Table 1. Outcomes for Rapid Cycle Analysis of COVID-19 mRNA Vaccines

Outcomes	Risk interval, d	Setting	Exclude if COVID-19 positive in the interval before vaccination, d ^a
Comparative analyses	1-21		
Acute disseminated encephalomyelitis		Emergency department, inpatient	NA
Acute myocardial infarction		Emergency department, inpatient	30
Appendicitis		Emergency department, inpatient	NA
Bell palsy		Emergency department, inpatient, outpatient	30
Cerebral venous sinus thrombosis		Emergency department, inpatient	30
Convulsions/seizures		Emergency department, inpatient	30
Disseminated intravascular coagulation		Emergency department, inpatient	42
Encephalitis/myelitis/encephalomyelitis		Emergency department, inpatient	30
Guillain-Barré syndrome		Emergency department, inpatient	NA
Immune thrombocytopenia		Emergency department, inpatient, outpatient	30
Kawasaki disease		Emergency department, inpatient	NA
Myocarditis/pericarditis		Emergency department, inpatient	30
Pulmonary embolism		Emergency department, inpatient	30
Stroke			
Hemorrhagic		Emergency department, inpatient	30
Ischemic		Emergency department, inpatient	30
Thrombosis with thrombocytopenia syndrome ^b		Emergency department, inpatient	30
Thrombotic thrombocytopenic purpura		Emergency department, inpatient	30
Transverse myelitis		Emergency department, inpatient	NA
Venous thromboembolism		Emergency department, inpatient, outpatient	30
Descriptive monitoring only	Monitoring period, d		
Acute respiratory distress syndrome	0-84	Emergency department, inpatient	42
Anaphylaxis	0-1	Emergency department, inpatient	NA
Multisystem inflammatory syndrome in children/adults	0-84	Emergency department, inpatient	NA
Narcolepsy/cataplexy	0-84	Emergency department, inpatient, outpatient	NA

Abbreviation: NA, not applicable.

^a Exclusion was applied to the entire population under surveillance. The rationale for excluding selected outcome events owing to recent COVID-19 infection was based on COVID-19 literature and subject matter expertise of outcomes known to be associated with COVID-19 infection. Timing of the exclusion period (30 or 42 days) was based on input from subject matter experts.

^b Outcome included cerebral venous sinus thrombosis, splanchnic vein thrombosis, and arterial thrombosis.

coagulation, multisystem inflammatory syndrome in children and adults, myocarditis/pericarditis, pulmonary embolism, stroke [hemorrhagic and ischemic], thrombotic thrombocytopenic purpura, and venous thromboembolism); or (4) emerging concerns that have arisen during the course of surveillance (cerebral venous sinus thrombosis,¹⁴ thrombosis with thrombocytopenia syndrome,¹⁵ and a younger subgroup of the myocarditis/pericarditis outcome¹⁶). We limited most outcomes to the emergency department and inpatient settings; however, we included immune thrombocytopenia, Bell palsy, narcolepsy, and venous thromboembolism diagnosed in the outpatient setting (Table 1). We used *International Statistical Classification of Diseases and Related Health Problems, 10th Revision* codes to identify outcomes and developed algorithms to ascertain incident cases based on prior studies, published literature, or expert opinion (eTables 1 and 2 in the Supplement). Where available, we also used an internal diagnostic code, “anaphylaxis due to

COVID-19 vaccine” (all settings, including outpatient), to supplement case identification; these patients were required to have also sought care in the emergency department or inpatient setting on days 0 to 1. Clinical subject matter experts consulted on case ascertainment criteria for all outcomes.

Medical Record Reviews

Surveillance activities included medical record reviews as needed to investigate potential signals or emerging concerns.

We prespecified that within 84 days after vaccination, all cases of Guillain-Barré syndrome, acute disseminated encephalomyelitis, transverse myelitis, cerebral venous sinus thrombosis, and myocarditis/pericarditis (among individuals aged 12-39 years) were to be reviewed and included in analyses only if confirmed. Medical record reviews were designed to ascertain both the diagnosis and the time of onset. We used the onset dates from these medical record reviews for the primary analysis.

All potential cases of anaphylaxis in vaccinated individuals during days 0 to 1 after vaccination also underwent a limited medical record review soon after identification to confirm diagnosis and exclude those with exposure to other known triggers (eg, peanut). This was followed by complete review 30 days later to include records from subsequent allergy and external health care encounters and adjudicated with the Brighton Collaboration criteria.¹⁷ Brighton criteria require sudden onset after vaccination, rapid progression of signs and symptoms, involvement of 2 or more organ systems, and no clear alternative etiology for anaphylaxis. To allow 30 days for a complete review, we included cases identified through May 29, 2021.

Statistical Analysis

We compared outcome incidence during a risk interval of days 1 to 21 after vaccination with outcome incidence in vaccinated concurrent comparators (eFigure 1 in the [Supplement](#)). These comparators were vaccinees who were concurrently—on the same calendar day—in a comparison interval that was 22 to 42 days after their most recent COVID-19 vaccination. For example, on March 1 individuals who were in their risk interval (eg, vaccinated from February 8-28) were compared with vaccinees who on March 1 had had their most recent dose 22 to 42 days earlier (eg, vaccinated January 18 to February 7). Vaccinees contributed to the primary analyses as exposed when in a 21-day risk interval after dose 1 or 2; they contributed as unexposed when in the comparison interval 22 to 42 days after their most recent dose. A similar comparison interval has been used in other vaccine safety studies.¹⁸ This interval is valuable to prioritize timely detection of an early elevated risk; a substantial delay before comparator follow-up was observable would delay timely detection. In addition, a longer delay postvaccination could increase the potential for bias arising from unmeasured factors associated with receiving vaccination earlier vs later.

To reduce the possibility of confounding by demographic factors and factors associated with calendar time, we conducted analyses within strata defined by 5-year age group, sex, 8 race and ethnicity groups (those missing race or ethnicity were categorized as unknown), site, and calendar day. Race and ethnicity was used to adjust for confounding that may have arisen if the factor was associated with vaccination dates and outcome events.

We used Poisson regression to estimate an adjusted rate ratio (RR) and corresponding 95% CI, estimating the incidence in the risk interval compared with incidence in the comparison interval, averaged over the strata and calendar days. We reported nominal 95% CIs rather than CIs widened to correspond with the sequential tests that are described later because nominal CIs are more interpretable in this surveillance. The study protocol specified that nominal CIs continue to be updated and reported regardless of whether any sequential test yielded a signal.

Each Poisson regression model was fitted to aggregated count data: on each calendar day in each age-sex-race-site stratum, we counted the numbers of vaccinees and outcomes in

the risk and comparison intervals. The dependent variable was the number of outcomes in the interval, the primary independent variable was whether the interval was a risk interval vs a comparison interval, and the offset term was the natural logarithm of the number of vaccinees in the interval. A stratum was informative only on a day when there was at least 1 person in the risk interval, at least 1 person in the comparison interval, and at least 1 outcome in either the risk interval or the comparison interval.

To estimate excess risk per million doses, we divided the risk interval's crude incidence rate by the adjusted RR, and then subtracted the result from the risk interval's crude incidence rate.

In this report, we feature analyses that combine follow-up after receipt of the BNT162b2 and mRNA-1273 vaccines and combine follow-up in the 21-day risk interval after dose 1 with follow-up in the 21-day risk interval after dose 2. Separate analyses were also conducted for each vaccine type and dose.

We conducted supplemental analyses to address emerging concerns about myocarditis/pericarditis, which included shorter risk intervals and examined temporal clustering of outcome events after vaccination, using the Kulldorff scan statistic.¹⁹

We also conducted supplemental analyses with unvaccinated concurrent comparators, using methods similar to those of the analyses with vaccinated concurrent comparators (eFigure 1 in the [Supplement](#)). For each calendar day, we compared the vaccinees in each age-sex-race-site stratum who were in the risk interval with all individuals in the same age-sex-race-site stratum who were unvaccinated on that calendar day. Analyses with unvaccinated comparators were considered supplemental—whereas vaccinated comparators were primary—under the assumption that vaccinees in the risk interval tended to be more similar to those in the comparison interval than to unvaccinated individuals (some of whom are unlikely ever to be vaccinated).

Supplemental analyses were intended to provide context for interpreting primary analyses and emerging concerns; they did not have a prespecified threshold for a statistical signal.

Sequential Testing

Sequential tests were conducted weekly. For all outcomes except anaphylaxis, acute respiratory distress syndrome, multisystem inflammatory syndrome, and narcolepsy (discussed later), we conducted 1-sided sequential tests of the null hypothesis that the vaccine did not affect risk during the risk interval. The threshold for a signal was 1-sided $P < .0048$ to keep the overall chance of making a type I error below .05 during 2 years of weekly analyses (according to a Pocock-style alpha-spending plan,²⁰ designed by simulation). A signal would end formal sequential testing but would not end surveillance activities for that outcome. Rather, surveillance would continue to help interpret the signal. The sequential test threshold was designed to account for the number of weekly tests of the same hypothesis, but not for the multiplicity of hypotheses across different outcomes. The multiplicity of different hypotheses

Table 2. Vaccine Doses Administered to the Surveillance Population, December 14, 2020-June 26, 2021

	BNT162b2 (N)		mRNA-1273 (N)		Both mRNA vaccines (N)			Surveillance population ≥ 12 y, No. ^a
	Dose 1	Dose 2	Dose 1	Dose 2	Dose 1	Dose 2	Total doses	
Total	3 539 611	3 214 737	2 636 202	2 454 578	6 175 813	5 669 315	11 845 128	10 162 227
Sex								
Female	1 909 585	1 738 663	1 435 437	1 341 000	3 345 022	3 079 663	6 424 685	5 326 063
Male	1 630 026	1 476 074	1 200 765	1 113 578	2 830 791	2 589 652	5 420 443	4 836 164
Age group, y								
12-15	213 814	152 494	0	0	213 814	152 494	366 308	558 130
16-17	139 660	120 488	0	0	139 660	120 488	260 148	280 784
18-49	1 624 340	1 468 324	1 171 064	1 065 998	2 795 404	2 534 322	5 329 726	5 124 940
50-64	816 597	760 201	719 892	676 251	1 536 489	1 436 452	2 972 941	2 329 719
65-74	438 496	417 945	450 819	429 666	889 315	847 611	1 736 926	1 139 752
≥ 75	306 704	295 285	293 929	282 290	600 633	577 575	1 178 208	728 902
Race and ethnicity								
American Indian/Alaska Native	10 296	9295	8349	7675	18 645	16 970	35 615	31 430
Asian	576 803	528 677	364 432	343 035	941 235	871 712	1 812 947	1 234 172
Black, non-Hispanic	184 621	163 717	150 120	137 608	334 741	301 325	636 066	668 516
Hispanic/Latino	767 978	679 008	616 513	567 361	1 384 491	1 246 369	2 630 860	2 509 139
Native Hawaiian/Pacific Islander	22 858	20 562	16 053	14 856	38 911	35 418	74 329	61 880
White, non-Hispanic	1 477 545	1 368 800	1 148 149	1 080 562	2 625 694	2 449 362	5 075 056	4 130 350
Multiple/other ^b	123 770	111 871	88 600	82 433	212 370	194 304	406 674	338 984
Unknown	375 740	332 807	243 986	221 048	619 726	553 855	1 173 581	1 187 756

^a Total enrolled population that has Emergency Use Authorization for existing COVID-19 vaccines. All enrolled persons aged 12 years or older are included in the weekly COVID-19 vaccine surveillance.

^b Includes persons with more than 1 non-Hispanic race and ethnicity and all other non-Hispanic races and ethnicities.

tested would be considered informally in the context of investigating signals. If there were a signal, it would be interpreted as exploratory insofar as the large number of hypotheses tested increases the possibility of a false-positive signal.

Descriptive Monitoring (No Comparators, RR Estimates, or Hypothesis Tests)

We conducted only descriptive monitoring for anaphylaxis, acute respiratory distress syndrome, multisystem inflammatory syndrome, and narcolepsy (ie, no RR estimates or hypothesis tests), given the lack of appropriate comparators. For these outcomes, we tabulated all observed cases that occurred within 84 days postvaccination.

For anaphylaxis, we also estimated the rate of confirmed anaphylaxis per million doses.

We used SAS version 9.4 (SAS Institute) for all analyses.

Results

From December 14, 2020, through June 26, 2021, 11 845 128 total doses of mRNA vaccines were administered to 6.2 million individuals (mean age, 49 years; 54% female). Of these, 6 754 348 were BNT162b2 and 5 090 780 were mRNA-1273 vaccines. There were 6 175 813 first doses and 5 669 315 second doses (Table 2). Overall, vaccinees aged 18 to 49 years received the largest number of doses (5 124 940); however, vac-

cination coverage was highest among members aged 75 years or older (82.4% with 1 dose; 79.2% with 2). Coverage was also higher among White and Asian persons compared with other racial and ethnic groups, including among the 11.7% of the surveillance population categorized as unknown race.

The number of outcome events during the 21-day risk interval ranged from 0 for Kawasaki disease to 1059 (1612 per 1 000 000 person-years) for ischemic stroke (Table 3). In weekly analyses, none of the outcomes met the signaling criteria of 1-sided $P < .0048$ (Table 3). In analyses through June 26, 2021, the incidence per 1 000 000 person-years during the risk and comparison intervals and adjusted RR ranged from 45 vs 69 (RR, 0.70; 95% CI, 0.39-1.28) for disseminated intravascular coagulation to 9 vs 6 (RR, 2.60; 95% CI, 0.47-20.66) for thrombotic thrombocytopenic purpura. For the most frequent outcomes, the incidence per 1 000 000 person-years during the risk vs comparison intervals and adjusted RR for ischemic stroke were 1612 vs 1781 (RR, 0.97; 95% CI, 0.87-1.08); for appendicitis, 1179 vs 1345 (RR, 0.82; 95% CI, 0.73-0.93); for acute myocardial infarction, 935 vs 1030 (RR, 1.02; 95% CI, 0.89-1.18); for venous thromboembolism, 952 vs 896 (RR, 1.16; 95% CI, 1.00-1.34); and for Bell palsy, 822 vs 825 (RR, 1.00; 95% CI, 0.86-1.17). The highest estimates of excess cases per million doses were 7.5 (95% CI, -0.1 to 14.0) for venous thromboembolism and 1.2 (95% CI, -6.9 to 8.3) for acute myocardial infarction (Table 3).

None of the 10 cerebral venous sinus thrombosis cases were associated with thrombocytopenia.

Table 3. Outcome Events in the 21-Day Risk Interval After Either Vaccine Dose Compared, on the Same Calendar Day, With Outcome Events in Individuals 22-42 Days After Their Most Recent Dose, December 14, 2020-June 26, 2021

Outcome	Events in risk interval (events/million person-years) ^a	Events in comparison interval (events/million person-years) ^{a,b}	Adjusted rate ratio ^c (95% CI) ^d	P value		Signal, 1-sided P < .0048 ^e	Excess cases in risk interval per million doses (95% CI) ^f
				2-Sided ^d	1-Sided		
Thrombotic thrombocytopenic purpura	6 (9.1)	2 (5.5)	2.60 (0.47-20.66)	.29	.23	No	0.3 (-0.6 to 0.5)
Cerebral venous sinus thrombosis ^g	7 (10.6)	3 (8.2)	1.55 (0.37-8.17)	.59	.41	No	0.2 (-1.1 to 0.5)
Transverse myelitis ^g	2 (3.0)	1 (2.7)	1.45 (0.10-47.73)	.82	.64	No	0.1 (-1.6 to 0.2)
Encephalitis/myelitis/encephalomyelitis	16 (25.7)	5 (13.7)	1.27 (0.45-4.10)	.69	.44	No	0.3 (-1.8 to 1.1)
Myocarditis/pericarditis	87 (131.7)	39 (106.9)	1.18 (0.79-1.79)	.44	.25	No	1.2 (-2.1 to 3.3)
Venous thromboembolism	626 (951.9)	327 (895.9)	1.16 (1.00-1.34)	.05	.03	No	7.5 (-0.1 to 14.0)
Immune thrombocytopenia	48 (72.6)	23 (63.0)	1.12 (0.65-1.97)	.70	.40	No	0.4 (-2.2 to 2.1)
Convulsions/seizures	285 (431.3)	150 (411.0)	1.04 (0.84-1.29)	.74	.39	No	0.9 (-4.8 to 5.6)
Acute myocardial infarction	613 (935.3)	375 (1030.2)	1.02 (0.89-1.18)	.75	.39	No	1.2 (-6.9 to 8.3)
Pulmonary embolism	503 (762.8)	290 (794.6)	1.01 (0.86-1.19)	.92	.48	No	0.4 (-7.2 to 6.9)
Bell palsy	535 (821.8)	301 (824.7)	1.00 (0.86-1.17)	.99	.52	No	0.0 (-7.9 to 6.7)
Stroke, ischemic	1059 (1611.8)	650 (1780.9)	0.97 (0.87-1.08)	.61	.70	No	-2.7 (-13.8 to 7.2)
Stroke, hemorrhagic	240 (364.7)	149 (408.2)	0.90 (0.72-1.13)	.37	.83	No	-2.3 (-8.3 to 2.5)
Thrombosis with thrombocytopenia syndrome	73 (112.0)	53 (145)	0.86 (0.58-1.27)	.45	.81	No	-1.0 (-4.6 to 1.4)
Appendicitis	762 (1178.9)	491 (1345.2)	0.82 (0.73-0.93)	.002	>.99	No	-14.8 (-25.5 to -5.3)
Guillain-Barré syndrome ^g	10 (15.1)	6 (16.4)	0.70 (0.22-2.31)	.53	.83	No	-0.4 (-3.0 to 0.5)
Disseminated intravascular coagulation	30 (45.4)	25 (68.5)	0.70 (0.39-1.28)	.25	.91	No	-1.1 (-4.1 to 0.6)
Kawasaki disease	0	2 (5.5)	0.00 (0.00-2.52)	.16	.16	No	-0.3 (-0.3 to 0.0)
Acute disseminated encephalomyelitis ^g	2 (3.0)	0	NE (0.07-NE)	.66	.66	No	0.2 (-2.5 to NE)

Abbreviation: NE, not estimable.

^a There were 660 766 person-years of follow-up in the risk interval and 364 988 person-years in the comparison interval.

^b Comparison interval was 22 to 42 days after either dose 1 or 2. The smaller case counts were due to the reduced available person-time of follow-up in the comparison interval. Most comparator follow-up was 22 to 42 days after dose 2 but some was 22 to 42 days after dose 1 in individuals who had not received dose 2.

^c Overall estimate from Poisson regression stratified by site, 5-year age group, sex, race and ethnicity, and calendar date.

^d CIs and P values do not account for the multiple chances for a false-positive signal during surveillance.

^e One-sided P < .0048 required for a signal. This keeps the probability of a false-positive signal (owing to chance alone) below .05 in 2 years of surveillance.

^f CIs for the excess risk estimates were based on the CIs of the corresponding adjusted rate ratios.

^g Only medical record-confirmed cases are included in the analysis.

None of the dose 1, dose 2, and vaccine product analyses met the signaling criteria of a 1-sided P < .0048 (eTable 3 in the Supplement).

During days 0 to 21 postvaccination, there were a total of 34 cases of confirmed myocarditis/pericarditis among individuals aged 12 to 39 years, of whom 53% were aged 12 to 24 years, 85% were male, 82% were hospitalized (median length of stay, 1 day), and nearly all were recovered at record review (eTable 4 in the Supplement). Cases were significantly clustered within the 0 to 5 days after vaccination (P < .001) (eFigure 2 in the Supplement). In supplemental analyses using vaccinated concurrent comparators, incidence per 1 000 000 person-years during the risk vs comparison intervals and adjusted RR were 321 vs 35 (RR, 9.83; 95% CI, 3.35-35.77) during days 0 to 7 after vaccination, corresponding to 6.3 additional cases per million doses (95% CI, 4.9-6.8) (Table 4). After dose 2, RR estimates were higher for both BNT162b2 and mRNA-1273 vaccines (eTable 5 in the Supplement).

Supplemental analyses among all ages, using unvaccinated comparators, were mostly consistent with the primary

vaccinated comparator analyses; however, for myocarditis/pericarditis, incidence per 1 000 000 person-years during the risk vs comparison intervals and adjusted RR were 132 vs 83 (RR, 1.39; 95% CI, 1.05-1.82) (eTable 6 in the Supplement).

Descriptive Monitoring

There were 183 potential anaphylaxis cases during days 0 to 1 after vaccination; 171 (93%) underwent full review and 55 (32%) were confirmed and adjudicated at Brighton level 1 to 3 (Table 5). Nearly all confirmed anaphylaxis cases were in female individuals (95%), occurred on the day of vaccination (98%), and occurred after dose 1 (82%); most individuals had a history of allergies (78%) and had symptom onset within 30 minutes (87%). The estimated incidence rate of confirmed anaphylaxis was 4.8 (95% CI, 3.2-6.9) per million BNT162b2 doses and 5.1 (95% CI, 3.3-7.6) per million mRNA-1273 doses.

During the 21 days after vaccination, 12 individuals received a diagnosis of acute respiratory distress syndrome, 6 of multisystem inflammatory syndrome, and 29 of narcolepsy; follow-up will continue through 84 days after vaccination.

Table 4. Confirmed Myocarditis/Pericarditis After Receipt of mRNA Vaccines Compared With Vaccinated Comparators Among Individuals Aged 12-39 Years by Dose and Risk Interval, December 14, 2020-June 26, 2021

Risk interval, d ^a	Dose	Events in risk interval (events/million person-years) ^b	Events in 21-d comparison interval ^{b,c} (events/million person-years) ^{b,c}	Adjusted rate ratio (95% CI) ^d	2-Sided P value	Excess cases in risk interval per million doses (95% CI) ^e
0-21	Both	34 (141.2)	4 (35.0)	3.75 (1.38 to 12.84)	.007	6.2 (2.3 to 7.8)
	1	9 (70.4)	4 (35.0)	3.67 (0.92 to 17.35)	.07	3.1 (-0.4 to 4.0)
	2	24 (221.3)	4 (44.6)	4.07 (1.45 to 14.18)	.005	10.1 (4.1 to 12.4)
0-7	Both	29 (320.8)	4 (35.0)	9.83 (3.35 to 35.77)	<.001	6.3 (4.9 to 6.8)
	1	5 (104.2)	3 (35.0)	7.27 (1.29 to 50.15)	.02	2.0 (0.5 to 2.2)
	2	23 (565.9)	4 (44.6)	10.4 (3.54 to 37.76)	<.001	11.2 (8.9 to 12.1)
8-14	Both	2 (25.7)	4 (35.0)	1.22 (0.14 to 7.74)	.82	0.1 (-3.0 to 0.4)
	1	2 (48.0)	3 (35.0)	3.25 (0.31 to 29.64)	.30	0.6 (-2.0 to 0.9)
	2	0	4 (44.6)	0 (0 to 3.22)	.28	-0.9 (-0.9 to 0)
15-21	Both	3 (41.3)	4 (35.0)	1.55 (0.28 to 7.78)	.58	0.3 (-2.0 to 0.7)
	1	2 (52.3)	4 (35.0)	2.58 (0.27 to 18.62)	.37	0.6 (-2.7 to 0.9)
	2	1 (29.1)	4 (44.6)	0.67 (0.03 to 5.64)	.79	-0.3 (-21.2 to 0.5)

Abbreviation: mRNA, messenger RNA.

^a In each "both" doses row, risk interval events were included if they occurred within the designated interval after either dose 1 or dose 2. In each row for dose 1, risk interval events were included if they occurred during the designated interval after dose 1; in each row for dose 2, risk interval events were included if they occurred during the designated interval after dose 2.

^b For a given risk interval, the sum of the events in the dose 1 and 2 rows may not add up to the number of events in the rows for both doses owing to rigorous adjustment by calendar date, site, age, sex, and race and ethnicity, as described in the Methods. In every row, events were included only if, on the calendar day of the event, the risk and comparison intervals each included at least 1 vaccinated person in the same site, 5-year age group, sex, and race and

ethnicity group (eFigure 1 in the Supplement). Similarly, events in the 21-day comparison interval column for dose 1 rows may differ from the number of events in the dose 2 rows.

^c Comparison interval for all analyses was 22 to 42 days after either dose 1 or 2. Most comparator follow-up was 22 to 42 days after dose 2 but some was 22 to 42 days after dose 1 in individuals who had not received dose 2.

^d Overall estimate from Poisson regression stratified by site, 5-year age group, sex, race and ethnicity, and calendar date.

^e CIs for the excess risk estimates were based on the CIs of the corresponding adjusted rate ratios.

Discussion

In this interim analysis of surveillance monitoring of more than 11.8 million doses of 2 mRNA vaccines in a diverse population and weekly analyses from December 14, 2020, to June 26, 2021, no vaccine-outcome association met the prespecified threshold for a signal. Incidence of selected serious outcomes was not significantly higher 1 to 21 days postvaccination compared with 22 to 42 days postvaccination for any of the outcomes. For the less frequent outcomes, CIs were wide and did not necessarily exclude clinically relevant increases associated with vaccination, and surveillance is ongoing.

This current surveillance complements other vaccine safety monitoring systems in the US, including the Vaccine Adverse Event Reporting System (VAERS) and v-safe.²¹ Key strengths of this surveillance are that it is population based, geographically diverse, and updated weekly. Outcome incidence among vaccinees in a risk interval was compared with outcome incidence among similar vaccinees who were in their comparison interval on the same calendar date. Thus, the comparison group for each outcome event was similar in demographic characteristics to the case and was in follow-up on the same day at the same site, avoiding biases that can arise from variations in health care use during the pandemic, as well as day-to-day variations (eg, Sunday to Monday). In addition, the primary analyses focused on vaccinated rather than unvaccinated comparators. Every vaccinee contributed to the pri-

mary analyses by first contributing to the risk interval and then to the comparison interval. Individuals with recent vaccination were expected to be more similar to those with more remote vaccination than they were to unvaccinated individuals, which, over time, was expected to yield comparisons that were better balanced than were comparisons of vaccinees with unvaccinated comparators. Furthermore, access to comprehensive medical records permitted rapid case confirmation when appropriate.

In response to concerns regarding an association between thromboembolic outcomes with thrombocytopenia and ChAdOx1 nCoV-19 (AstraZeneca)^{22,23} and Ad26.COV.2.S (Janssen) vaccines,^{14,15} surveillance for additional outcomes (cerebral venous sinus thrombosis and thrombosis with thrombocytopenia syndrome) was initiated. There has been no evidence that these outcomes are associated with mRNA vaccines. Close monitoring will continue for thromboembolic outcomes with thrombocytopenia after vaccination with all COVID-19 vaccines, including the Ad26.COV.2.S vaccine.

Analyses of all ages combined did not detect a significant association between myocarditis/pericarditis and mRNA vaccines. However, consistent with case reports,^{16,24} supplemental analyses of confirmed cases among individuals aged 12 to 39 years yielded an elevated RR estimate. Significant clustering within the first week after vaccination, especially after dose 2, provides additional evidence of an association between mRNA vaccines and myocarditis/pericarditis in younger individuals.

Table 5. Confirmed Anaphylaxis Cases After Medical Record Review Through May 29, 2021^a

	No. (%)	
	BNT162b2 (n = 30)	mRNA-1273 (n = 25)
Age, mean (SD), y	42.8 (14.5)	45.7 (15.5)
Female sex	30 (100)	22 (88)
Time from vaccination to symptom onset, median (IQR) [N], min ^b	10.0 (5.0-20.0) [21]	10.0 (5.0-20.5) [20]
Time to symptom onset, min		
≤15 ^b	19 (63)	17 (68)
≤30 ^b	26 (87)	22 (88)
History		
Allergies ^c	24 (80)	19 (76)
Anaphylaxis ^d	15 (50)	5 (20)
Dose		
1	25 (83)	20 (80)
2	5 (17)	5 (20)
Brighton Collaboration case definition level ^e		
1, High certainty	13 (43)	6 (24)
2, Moderate certainty	17 (57)	18 (72)
3, Low certainty	0	1 (4)
Confirmed anaphylaxis cases per million doses (95% CI) ^f	4.8 (3.2-6.9)	5.1 (3.3-7.6)
Confirmed anaphylaxis cases per million doses among female individuals (95% CI) ^f	8.9 (6.0-12.7)	8.6 (5.2-12.5)

^a Includes 11 cases identified through internal diagnostic codes, 5 after vaccination with BNT162b2 and 6 after mRNA-1273.

^b Although exact timing was not available for all cases, it was classifiable as within 15 or 30 minutes for all cases, according to available notes in the medical record. For example, symptom onset was noted as beginning "shortly after" vaccination for 2 cases; these were classified as symptom onset within 30 minutes.

^c History of allergies included other vaccine (n = 8), bee sting (n = 4), nuts (n = 7), other food (n = 15), food additive (n = 2), antibiotic (n = 25), contrast (n = 3), other medication (n = 23), latex (n = 8), and cats (n = 1). Additionally, 1 person was noted as having an allergy to polyethylene glycol.

^d History of anaphylaxis included other vaccine (n = 3), bee sting (n = 4), nuts (n = 3), other food (n = 5), food additive (n = 2), antibiotic (n = 7), contrast (n = 2), other medication (n = 5), and latex (n = 1).

^e The Brighton criteria required that the patient experienced sudden onset of anaphylaxis after vaccination, had rapid progression of signs and symptoms, had involvements of multiple (2 or more) organ systems, and had no clear alternative etiology or diagnosis for the event. The case definition is further divided into 3 levels of diagnostic certainty based on specific signs/symptoms and organ systems involved, with level 1 being the highest level of certainty.

^f Cases classified as Brighton level 1, 2, or 3 after adjudication were considered confirmed.

Anaphylaxis after COVID-19 mRNA vaccination has been observed more commonly than the estimated 1 to 2 cases per million doses reported after receipt of influenza vaccine and some other vaccines.²⁵ Estimated anaphylaxis incidence rates after receipt of both BNT162b2 and mRNA-1273 vaccines in this study were similar to rates after receipt of mRNA vaccines in other reports,^{21,26} although somewhat higher than VAERS estimated reporting rates.²⁷ In contrast, estimated anaphylaxis incidence rates were much lower than the 24.7 cases of con-

firmed anaphylaxis per 100 000 vaccinees estimated through prospective surveillance of health care workers.²⁸ Consistent with reports from the European Union and Japan,²⁹ nearly all anaphylaxis after receipt of mRNA vaccines occurred among female recipients. Although the biological mechanism for the higher incidence among female vaccinees is not clear, it may be related to genes, hormones, and environmental and immunologic factors.³⁰

The phase 3 trials for both the BNT162b2 and mRNA-1273 vaccines noted that the incidence of Bell palsy was higher in the vaccine group than in the placebo group.^{3,4} Among nearly 40 000 vaccinees in both trials combined, there were 7 cases of Bell palsy vs 1 in the placebo group, corresponding to an RR of 7 ($P = .07$).³¹ In this current surveillance, neither the primary analyses nor those with unvaccinated comparators found evidence of an association between Bell palsy and mRNA vaccines, a finding that is consistent with a recent analysis of cases reported to the World Health Organization database.³²

Limitations

This study has several limitations. First, the statistical power of these early analyses was limited, especially for the less frequent outcomes. The 95% CIs around some of the RR estimates were wide and included clinically relevant risks. Six outcomes in the primary analyses yielded CIs that included RR estimates greater than 2.0, levels that may be clinically important even if outweighed by the COVID-19 outcomes prevented. During the next few months, the precision of the RR estimates will improve as follow-up accumulates. Second, vaccinees contributed follow-up in the risk interval before they contributed it in the comparison interval, and bias might arise if unmeasured variables associated with earlier vaccination were also associated with having an outcome. Third, there may be interest in specific outcomes that were not initially included or were included within a much broader category. However, additional outcomes were added in response to emerging concerns. Fourth, risk may be underestimated or missed if the real risk interval was modestly longer (ie, 1 week) beyond 21 days after exposure to a first or second dose or perhaps several weeks longer. Fifth, although vaccinees were followed for several months after vaccination, possible longer-term risks of vaccination were not being monitored. Sixth, only medically attended outcomes were included; thus, analyses could have underestimated risk if health care was not sought. Although the outcomes monitored are serious and usually associated with seeking care, anaphylaxis incidence may have been underestimated if individuals either received care in alternate settings or self-treated at the event.

Conclusions

In interim analyses of surveillance of mRNA COVID-19 vaccines, incidence of selected serious outcomes was not significantly higher 1 to 21 days postvaccination compared with 22 to 42 days postvaccination. While CIs were wide for many outcomes, surveillance is ongoing.

ARTICLE INFORMATION

Accepted for Publication: August 18, 2021.

Published Online: September 3, 2021.
doi:10.1001/jama.2021.15072

Author Affiliations: Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland (Klein, Lewis, Goddard, Fireman, Zerbo); Marshfield Clinic Research Institute, Marshfield, Wisconsin (Hanson, Donahue); HealthPartners Institute, Minneapolis, Minnesota (Kharbanda); Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon (Naleway); Biostatistics Unit, Kaiser Permanente Washington Health Research Institute, Seattle, Washington (Nelson); Research and Evaluation, Kaiser Permanente Southern California, Pasadena (Xu, Lewin); Harvard Pilgrim Health Care Institute, Boston, Massachusetts (Yih); Institute for Health Research, Kaiser Permanente Colorado, Denver (Glanz); Department of Epidemiology, Colorado School of Public Health, Aurora (Glanz); Ambulatory Care Services, Denver Health, Denver, Colorado (Williams, Hambidge); University of Colorado School of Medicine, Aurora (Williams, Hambidge); Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia (Shimabukuro, DeStefano, Weintraub).

Author Contributions: Dr Klein had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Klein, Lewis, Goddard, Fireman, Zerbo, Naleway, Nelson, Shimabukuro, DeStefano, Weintraub.

Acquisition, analysis, or interpretation of data: Lewis, Goddard, Fireman, Zerbo, Hanson, Donahue, Kharbanda, Naleway, Nelson, Xu, Yih, Glanz, Williams, Hambidge, Lewin, Shimabukuro, DeStefano, Weintraub.

Drafting of the manuscript: Klein, Lewis, Goddard, Fireman, Weintraub.

Critical revision of the manuscript for important intellectual content: Lewis, Goddard, Fireman, Zerbo, Hanson, Donahue, Kharbanda, Naleway, Nelson, Xu, Yih, Glanz, Williams, Hambidge, Lewin, Shimabukuro, DeStefano, Weintraub.

Statistical analysis: Lewis, Fireman, Nelson, Xu, Glanz, Lewin, Weintraub.

Obtained funding: Klein, Goddard, Zerbo, Hanson, Donahue, Weintraub.

Administrative, technical, or material support: Goddard, Hanson, Donahue, Yih, Hambidge, Shimabukuro, Weintraub.

Supervision: Klein, Hambidge, Shimabukuro, DeStefano, Weintraub.

Case review and adjudication, vaccine capture in the health record: Lewin.

Conflict of Interest Disclosures: Dr Klein reported receiving grants from the Centers for Disease Control and Prevention (CDC) during the conduct of the study, and grants from Pfizer, Merck, GSK, Sanofi Pasteur, and Protein Science (now SP) outside the submitted work. Ms Hanson reported receiving grants from CDC during the conduct of the study. Dr Donahue reported receiving grants from CDC during the conduct of the study and from Janssen Vaccines & Prevention for a study unrelated to COVID-19 vaccines. Dr Kharbanda reported receiving other from CDC (contract 200-2012-53526) during the conduct of the study.

Dr Naleway reported receiving grants from CDC during the conduct of the study and grants from Pfizer outside the submitted work. Dr Nelson reported receiving grants from Moderna outside the submitted work. Dr Yih reported receiving grants from Pfizer outside the submitted work. Dr Williams reported receiving grants from CDC Vaccine Safety Datalink COVID-19 Infrastructure Funding during the conduct of the study. Dr Lewin reported receiving grants from CDC Vaccine Safety Datalink during the conduct of the study. No other disclosures were reported.

Funding/Support: This study was supported by grant funding from the CDC, contract 200-2012-53581/0001.

Role of the Funder/Sponsor: The study sponsor, CDC, participated as a coinvestigator and contributed to protocol development, conduct of the study, interpretation of the data, review and revision of the manuscript, approval of the manuscript through official CDC scientific clearance processes, and the decision to submit the manuscript for publication. CDC authors must receive approval through the CDC scientific clearance process to submit an article for publication. Final decision to submit rested with the first author. The study sponsor did not have the right to direct the submission to a particular journal.

Disclaimer: The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the CDC. Mention of a product or company name is for identification purposes only and does not constitute endorsement by CDC.

Additional Contributions: We thank Ed Belongia, MD (Marshfield Clinic Research Institute) for providing clinical expertise for this manuscript. We thank Rachael Burganowski, MS (Kaiser Permanente Washington Health Research Institute), Bradley Crane, MS (Center for Health Research, Kaiser Permanente Northwest), Sungching Glenn, MS (Research and Evaluation, Kaiser Permanente Southern California), Tat'Yana Kenigsberg, MPH (Immunization Safety Office, Centers for Disease Control and Prevention), Erica Scotty, MS (Marshfield Clinic Research Institute), Gabriela Vazquez Benitez, PhD (HealthPartners Institute), Arnold Yee, BS (Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California), and Jingyi Zhu, PhD (HealthPartners Institute), for their contributions to data collection and preparation. We thank Nandini Bakshi, MD (The Permanente Medical Group), Tom Boyce, MD (Marshfield Clinic Research Institute), Jennifer Covey, BS (Kaiser Permanente Washington Health Research Institute), Jonathan Duffy, MD (Immunization Safety Office, Centers for Disease Control and Prevention), Stacy Harsh, BSN, RN (Center for Health Research, Kaiser Permanente Northwest), Linda Heeren, BS (Marshfield Clinic Research Institute), Juraj Kavecansky, MD (Kaiser Permanente Northern California, Antioch Medical Center), Mike M. McNeil, MD (Immunization Safety Office, Centers for Disease Control and Prevention), Tanya Myers, PhD (Immunization Safety Office, Centers for Disease Control and Prevention), Matthew E. Oster, MD, MPH (Centers for Disease Control and Prevention, COVID-19 Response), Ashok Pai, MD (Kaiser Permanente Northern California, Oakland Medical Center), and

Pat Ross, BA (Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California), for their contributions to medical record review and adjudication. We thank Laurie Aukes, RN (Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California), Cheryl Carlson, MPH (Research and Evaluation, Kaiser Permanente Southern California), Stephanie Irving, MHS (Center for Health Research, Kaiser Permanente Northwest), Mara Kalter, MA (Center for Health Research, Kaiser Permanente Northwest), Tia Kauffman, MPH (Center for Health Research, Kaiser Permanente Northwest), Erika Kiniry, MPH (Kaiser Permanente Washington Health Research Institute), Leslie Kuckler, MPH (HealthPartners Institute), Denison Ryan, MPH (Research and Evaluation, Kaiser Permanente Southern California), and Lina Sy, MPH (Research and Evaluation, Kaiser Permanente Southern California), for their contributions to overall project management. All non-CDC personnel received financial compensation through CDC Vaccine Safety Datalink grant funding for their work on this project. CDC personnel were not compensated for their role in the study.

REFERENCES

- Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices' interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine—United States, December 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(50):1922-1924. doi:10.15585/mmwr.mm6950e2
- Oliver SE, Gargano JW, Marin M, et al. The Advisory Committee on Immunization Practices' interim recommendation for use of Moderna COVID-19 vaccine—United States, December 2020. *MMWR Morb Mortal Wkly Rep.* 2021;69(5152):1653-1656. doi:10.15585/mmwr.mm695152e1
- Polack FP, Thomas SJ, Kitchin N, et al; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med.* 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
- Baden LR, El Sahly HM, Essink B, et al; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med.* 2021;384(5):403-416. doi:10.1056/NEJMoa2035389
- Dooling K, Marin M, Wallace M, et al. The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 vaccine—United States, December 2020. *MMWR Morb Mortal Wkly Rep.* 2021;69(5152):1657-1660. doi:10.15585/mmwr.mm695152e2
- O'Callaghan KP, Blatz AM, Offit PA. Developing a SARS-CoV-2 vaccine at warp speed. *JAMA.* 2020;324(5):437-438. doi:10.1001/jama.2020.12190
- Baggs J, Gee J, Lewis E, et al. The Vaccine Safety Datalink: a model for monitoring immunization safety. *Pediatrics.* 2011;127(suppl 1):S45-S53. doi:10.1542/peds.2010-1722H
- Lieu TA, Kulldorff M, Davis RL, et al; Vaccine Safety Datalink Rapid Cycle Analysis Team. Real-time vaccine safety surveillance for the early detection of adverse events. *Med Care.* 2007;45(10)(suppl 2):S89-S95. doi:10.1097/MLR.Ob013e3180616c0a
- Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination

- vaccine and the risk of febrile seizures. *Pediatrics*. 2010;126(1):e1-e8. doi:10.1542/peds.2010-0665
10. Weintraub ES, Baggs J, Duffy J, et al. Risk of intussusception after monovalent rotavirus vaccination. *N Engl J Med*. 2014;370(6):513-519. doi:10.1056/NEJMoa1311738
11. Donahue JG, Kieke BA, Lewis EM, et al. Near real-time surveillance to assess the safety of the 9-valent human papillomavirus vaccine. *Pediatrics*. 2019;144(6):e20191808. doi:10.1542/peds.2019-1808
12. Yoon P, Hall J, Fuld J, et al. Alternative methods for grouping race and ethnicity to monitor COVID-19 outcomes and vaccination coverage. *MMWR Morb Mortal Wkly Rep*. 2021;70(32):1075-1080. doi:10.15585/mmwr.mm7032a2
13. Pingali C, Meghani M, Razzaghi H, et al. COVID-19 vaccination coverage among insured persons aged ≥ 16 years, by race/ethnicity and other selected characteristics—eight integrated health care organizations, United States, December 14, 2020–May 15, 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(28):985-990. doi:10.15585/mmwr.mm7028a1
14. Cases of cerebral venous sinus thrombosis with thrombocytopenia after receipt of the Johnson & Johnson COVID-19 vaccine. Centers for Disease Control and Prevention. Published April 13, 2021. Accessed April 20, 2021. <https://emergency.cdc.gov/han/2021/han00442.asp>
15. EMA raises awareness of clinical care recommendations to manage suspected thrombosis with thrombocytopenia syndrome. European Medicines Agency. Published June 7, 2021. Accessed June 29, 2021. <https://www.ema.europa.eu/en/news/ema-raises-awareness-clinical-care-recommendations-manage-suspected-thrombosis-thrombocytopenia>
16. Marshall M, Ferguson ID, Lewis P, et al. Symptomatic acute myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination. *Pediatrics*. 2021;e2021052478. doi:10.1542/peds.2021-052478
17. Rüggeberg JU, Gold MS, Bayas JM, et al; Brighton Collaboration Anaphylaxis Working Group. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. *Vaccine*. 2007;25(31):5675-5684. doi:10.1016/j.vaccine.2007.02.064
18. Lee GM, Greene SK, Weintraub ES, et al H1N1 and seasonal influenza vaccine safety in the Vaccine Safety Datalink project. *Am J Prev Med*. 2011;41(2):121-128. doi:10.1016/j.amepre.2011.04.004
19. Kulldorff M, Nagarwalla N. Spatial disease clusters: detection and inference. *Stat Med*. 1995;14(8):799-810. doi:10.1002/sim.4780140809
20. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. *Biometrika*. 1977;64(2):191-199. doi:10.1093/biomet/64.2.191
21. Gee J, Marquez P, Su J, et al. First month of COVID-19 vaccine safety monitoring—United States, December 14, 2020–January 13, 2021. *MMWR Morb Mortal Wkly Rep*. 2021;70(8):283-288. doi:10.15585/mmwr.mm7008e3
22. Schultz NH, Sørvoll IH, Michelsen AE, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. *N Engl J Med*. 2021;384(22):2124-2130. doi:10.1056/NEJMoa2104882
23. Pottegård A, Lund LC, Karlstad Ø, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. *BMJ*. 2021;373(n1114):n1114. doi:10.1136/bmj.n1114
24. Muthukumar A, Narasimhan M, Li QZ, et al. In-depth evaluation of a case of presumed myocarditis after the second dose of COVID-19 mRNA vaccine. *Circulation*. 2021;144(6):487-498. doi:10.1161/CIRCULATIONAHA.121.056038
25. McNeil MM, Weintraub ES, Duffy J, et al Risk of anaphylaxis after vaccination in children and adults. *J Allergy Clin Immunol*. 2016;137(3):868-878. doi:10.1016/j.jaci.2015.07.048
26. CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine—United States, December 14-23, 2020. *MMWR Morb Mortal Wkly Rep*. 2021;70(2):46-51. doi:10.15585/mmwr.mm7002e1
27. Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US—December 14, 2020–January 18, 2021. *JAMA*. 2021;325(11):1101-1102. doi:10.1001/jama.2021.1967
28. Blumenthal KG, Robinson LB, Camargo CA Jr, et al. Acute allergic reactions to mRNA COVID-19 vaccines. *JAMA*. 2021;325(15):1562-1565. doi:10.1001/jama.2021.3976
29. Somiya M, Mine S, Yasukawa K, Ikeda S. Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines. *Vaccine*. 2021;39(25):3313-3314. doi:10.1016/j.vaccine.2021.04.066
30. De Martinis M, Sirufo MM, Suppa M, Di Silvestre D, Ginaldi L. Sex and gender aspects for patient stratification in allergy prevention and treatment. *Int J Mol Sci*. 2020;21(4):E1535. doi:10.3390/ijms21041535
31. Ozonoff A, Nanishi E, Levy O. Bell's palsy and SARS-CoV-2 vaccines. *Lancet Infect Dis*. 2021;21(4):450-452. doi:10.1016/S1473-3099(21)00076-1
32. Renoud L, Khouri C, Revol B, et al. Association of facial paralysis with mRNA COVID-19 vaccines: a disproportionality analysis using the World Health Organization pharmacovigilance database. *JAMA Intern Med*. 2021;e212219. doi:10.1001/jamainternmed.2021.2219